We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
Read MoreHide Full Article
Medidata Solutions Inc. , a leading global provider of clinical development solutions, recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company. The duo would collaborate on the development of patient-centric technology and clinical trial expertise for the biopharmaceutical industry.
Stock Performance
The price performance of the stock has been favorable in the last three months. Medidata Solutions has returned 38.15%, outperforming the Zacks classified Medical Information System sub-industry’s gain of almost 16.54%.
The estimate revision trend for the current year has been favorable as four estimates have moved north in the last two months compared with no movement in the opposite direction. We are also optimistic about the long-term growth of the company which is pegged at 21.14%. The company has projected sales growth of 19.30%, which is higher than the industry’s average of 8.65%.
Coming back to the news, we feel that the partnership is a smart move on the part of Medidata Solutions. This is because it will broaden the reach of Medidata’s electronic informed consent technology known as Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide.
With inVentiv Health’s ability to support clients in 90 countries, having developed or commercialized 82% of new drugs approved by the FDA in the last five years, the strategic partnership is also expanding Medidata’s reach to sponsors all over the globe.
Zacks Rank & Key Picks
Currently, Medidata carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy) while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 102.3%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock delivered a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 81.8%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks ""Strong Sells"" absolutely free >>
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
Medidata Solutions Inc. , a leading global provider of clinical development solutions, recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company. The duo would collaborate on the development of patient-centric technology and clinical trial expertise for the biopharmaceutical industry.
Stock Performance
The price performance of the stock has been favorable in the last three months. Medidata Solutions has returned 38.15%, outperforming the Zacks classified Medical Information System sub-industry’s gain of almost 16.54%.
The estimate revision trend for the current year has been favorable as four estimates have moved north in the last two months compared with no movement in the opposite direction. We are also optimistic about the long-term growth of the company which is pegged at 21.14%. The company has projected sales growth of 19.30%, which is higher than the industry’s average of 8.65%.
Coming back to the news, we feel that the partnership is a smart move on the part of Medidata Solutions. This is because it will broaden the reach of Medidata’s electronic informed consent technology known as Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide.
With inVentiv Health’s ability to support clients in 90 countries, having developed or commercialized 82% of new drugs approved by the FDA in the last five years, the strategic partnership is also expanding Medidata’s reach to sponsors all over the globe.
Zacks Rank & Key Picks
Currently, Medidata carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy) while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 102.3%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock delivered a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 81.8%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks ""Strong Sells"" absolutely free >>
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>